Repligen (NASDAQ:RGEN) Shares Gap Down – Here’s What Happened

Repligen Co. (NASDAQ:RGEN)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $148.59, but opened at $144.96. Repligen shares last traded at $147.59, with a volume of 31,838 shares traded.

Wall Street Analyst Weigh In

Several research analysts have issued reports on RGEN shares. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Wednesday. Wolfe Research started coverage on Repligen in a report on Thursday. They set a “peer perform” rating on the stock. Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Price Performance

The firm has a market cap of $7.98 billion, a price-to-earnings ratio of -384.94, a P/E/G ratio of 4.27 and a beta of 0.96. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average of $141.59 and a 200 day moving average of $144.78.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.23 EPS. Equities research analysts predict that Repligen Co. will post 1.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of large investors have recently added to or reduced their stakes in RGEN. Champlain Investment Partners LLC increased its holdings in Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after acquiring an additional 425,061 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after acquiring an additional 199,322 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Repligen by 39.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after acquiring an additional 121,305 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.